⚠️ Multiple Gestation Twin-to-Twin Transfusion Simulator

Monochorionic Placentation and the Oligohydramnios-Polyhydramnios Sequence

Twin-to-twin transfusion syndrome (TTTS) complicates 10–15% of monochorionic diamniotic (MCDA) twin pregnancies and arises from unbalanced blood flow across unpaired vascular anastomoses within the single shared placental mass. Diagnosis is entirely ultrasonographic: chorionicity must be established in the first trimester, because TTTS is a diagnosis that can only occur when two fetuses share one chorion.

• ~1 in 400: MCDA incidence (pregnancies; ~70% of MC twins)
• 10–15%: TTTS incidence in MCDA (of monochorionic twin pairs)
• 10–14 wks: Best window for chorionicity (T-sign vs lambda/twin-peak sign)
• 80–90%: Untreated perinatal mortality (for Quintero III–IV if untreated)

Chorionicity determination and vascular anatomy of the shared placenta

First-trimester ultrasound (10–14 weeks) is the single most important determinant of twin pregnancy management, because chorionicity — not zygosity — dictates surveillance intensity and risk.

Sonographic chorionicity signs: • Lambda (twin-peak) sign: triangular tongue of chorionic tissue extending between the amnions at the inter-twin membrane base → dichorionic • T-sign: thin membrane meets the placenta at a sharp right angle with no intervening chorion → monochorionic • Membrane thickness, layer count, and number of placental masses are all less reliable after the first trimester as the lambda sign can regress

Vascular anatomy of the monochorionic placenta: • All MC placentas contain vascular anastomoses connecting the two fetal circulations across the chorionic plate — these are near-universal, present in >95% of MC placentas • Three anastomosis types: artery-to-artery (AA), vein-to-vein (VV), and artery-to-vein (AV) • AA and VV anastomoses are superficial, bidirectional, and net hemodynamically protective — they allow flow to equalize in either direction • AV anastomoses are deep, unidirectional (blood enters a cotyledon via one twin's artery and drains via the other twin's vein), and are the pathologic substrate of TTTS • TTTS develops when AV anastomoses are unbalanced (net flow favors one twin) and are not adequately compensated by protective AA anastomoses — placentas with a large AA anastomosis are relatively protected from TTTS

Pathophysiologic sequence: • Donor twin: chronic net blood loss → hypovolemia → decreased renal perfusion → oliguria → oligohydramnios, and eventually anhydramnios with the donor becoming "stuck" against the uterine wall by its collapsed membrane • Recipient twin: chronic net blood gain → hypervolemia → increased renal perfusion → polyuria → polyhydramnios; volume overload triggers a renin-angiotensin-aldosterone and natriuretic peptide cascade producing hypertension, ventricular hypertrophy, AV valve regurgitation, and eventually cardiomyopathy

Quintero Stage I — The Mildest Form of Oligohydramnios-Polyhydramnios Sequence

The Quintero staging system (1999) remains the standard framework for describing TTTS severity, even though it is not strictly linear in prognosis or progression — some pregnancies skip stages or fluctuate. Stage I is defined purely by the fluid discordance criteria: donor MVP ≤2cm and recipient MVP ≥8cm (≥10cm after 20 weeks in some series), with a visible donor bladder and normal Doppler studies in both twins.

• ≤2 cm: Donor MVP threshold (defines oligohydramnios)
• ≥8 cm: Recipient MVP threshold ((≥10cm after 20wks by some criteria))
• ~15%: Spontaneous stabilization (of Stage I regress or plateau)
• ~86%: Survival with expectant mgmt (in stable, closely monitored Stage I)

Diagnostic criteria and the case for laser vs expectant management in Stage I

Quintero Stage I criteria: • Donor: MVP ≤2cm (oligohydramnios) with bladder still visualized • Recipient: MVP ≥8cm (polyhydramnios) • Doppler: normal umbilical artery, ductus venosus, and middle cerebral artery waveforms in BOTH fetuses • No hydrops in either twin

Management controversy: The optimal management of Stage I TTTS is genuinely debated because outcomes with expectant management (serial ultrasound every 1–2 weeks) are reasonably good, and not all Stage I cases progress. However, a substantial minority (30–40%) progress to higher stages, and progression can be rapid (days). Factors favoring earlier laser referral: short cervix, recipient cardiac dysfunction on detailed echo even if Doppler is "normal" by Quintero criteria, maternal respiratory or abdominal discomfort from severe polyhydramnios, and gestational age still within the 16–26 week laser window.

All Stage I patients should be referred to (or co-managed with) a fetal therapy center capable of laser, so that if progression occurs, treatment is not delayed by a referral process.

Quintero Stage II — Donor Bladder Non-Visualization

Stage II is defined by non-visualization of the donor bladder over a 30–60 minute scanning window, reflecting near-anuria from severe donor hypovolemia and renal hypoperfusion, while Doppler studies remain within normal limits in both twins. This stage marks a meaningful worsening of donor renal and volume status even though objective Doppler markers of cardiovascular compromise have not yet appeared.

• 30–60 min: Bladder non-visualization window (required before calling Stage II)
• Near-zero: Donor urine output (severe hypovolemic renal hypoperfusion)
• >75%: Progression risk untreated (to Stage III–IV without laser)
• ~85–90%: Laser survival (≥1 twin) (when performed at Stage II)

Why Stage II warrants intervention despite "normal" Doppler

Bladder non-visualization is a sensitive marker of donor circulatory compromise that precedes overt Doppler abnormality. Because progression from Stage II to Stage III–V is common and can occur over days, most contemporary fetal therapy centers recommend fetoscopic laser photocoagulation for Stage II rather than continued expectant management, particularly beyond 18 weeks gestation.

The Solomon trial and subsequent registry data established laser as superior to serial amnioreduction across Quintero stages, but the absolute benefit is most dramatic for Stage II–IV, where laser roughly doubles the chance both twins survive compared with amnioreduction alone.

Quintero Stage III — Critically Abnormal Doppler Studies

Stage III introduces objective Doppler evidence of cardiovascular decompensation in either twin: absent or reversed end-diastolic flow in the donor umbilical artery (reflecting elevated placental vascular resistance from donor hypovolemia), reversed flow in the ductus venosus a-wave, or pulsatile umbilical venous flow — both signaling recipient cardiac dysfunction from chronic volume overload.

• AREDF: Donor UA finding (absent/reversed end-diastolic flow)
• Reversed a-wave: Recipient DV finding (reflects diastolic dysfunction)
• Pulsatile flow: Recipient UV finding (transmitted atrial pressure waves)
• Days, not weeks: Laser urgency (schedule expeditiously)

Interpreting critically abnormal Doppler in donor vs recipient twins

The donor twin's abnormal umbilical artery Doppler reflects the placental territory perfusing the donor becoming progressively smaller and higher-resistance as net flow is diverted to the recipient — the donor is, in effect, being starved of both blood volume and placental surface area.

The recipient twin's ductus venosus and umbilical vein findings reflect a very different mechanism: volume overload leading to diastolic dysfunction, elevated central venous pressure, and eventually functional tricuspid regurgitation. These findings can coexist — a Stage III diagnosis requires only ONE of these findings in EITHER twin, not all of them, and it does not require both fluid criteria and Doppler criteria to be simultaneously worsening.

Quintero staging is not strictly sequential: a pregnancy can jump from Stage I directly to Stage III, and donor and recipient abnormalities do not need to arise in lockstep. Stage assignment is made from the single worst finding present at the time of scanning.

Quintero Stage IV and V — Hydrops Fetalis and Co-Twin Demise

Stage IV is defined by hydrops in either twin — most often the recipient, from high-output cardiac failure and AV valve regurgitation, though donor hydrops can occur from severe anemia or asphyxia. Stage V denotes demise of one or both twins. Because the twins share a circulation via anastomoses until delivery or laser separation, the death of one twin exposes the survivor to acute hemodynamic collapse through the still-patent shared vessels.

• ≥2 compartments: Hydrops definition (effusion, ascites, skin edema, hydrops placenta)
• 18–30%: Co-twin injury risk after demise (neurologic injury in survivor)
• ~15%: Co-twin death risk after demise (if untreated, single antecedent demise)
• Acute hypotension: Time-critical mechanism (survivor exsanguinates into dead co-twin)

Mechanism of co-twin injury and management at Stage IV/V

When one MC twin dies, the surviving twin's blood pressure acutely equilibrates with the now-atonic, low-resistance vascular bed of the dead co-twin through patent AA/VV anastomoses, causing acute survivor hypotension and hypoperfusion — this occurs within minutes of demise, not days, which is why antenatal monitoring cannot reliably prevent it once demise has occurred.

Stage IV management: emergent laser photocoagulation remains first-line if the pregnancy is within the treatment window and hydrops is not yet severe/irreversible; delivery is considered if gestational age favors neonatal survival over continued in-utero risk.

Stage V management: once one twin has died, the priority shifts to protecting the survivor — urgent MCA Doppler and neuroimaging (MRI at least 4 weeks after the event) to assess for anemia and neurologic injury, with delivery timing individualized to gestational age and survivor status. Laser is no longer indicated once a co-twin has died, since the therapeutic goal (preventing feto-fetal transfusion) has been overtaken by the shared-circulation emergency itself.

Because Stage V risk is driven by the acute hemodynamic event of demise rather than ongoing transfusion, prevention — timely laser at Stage II–III — is far more effective than any intervention available after a co-twin has already died.

Fetoscopic Laser Photocoagulation — Definitive Treatment for TTTS

Fetoscopic laser photocoagulation of the vascular equator, using the Solomon technique (a continuous line of ablation along the entire visible vascular equator rather than selective ablation of only the anastomoses identified), is the standard of care for Quintero Stage II–IV TTTS diagnosed between roughly 16 and 26 weeks gestation, and converts a functionally shared circulation into two independent ones.

• 16–26 wks: Optimal treatment window (earlier/later handled at specialized centers)
• ~85–90%: ≥1 twin survival, laser (contemporary series)
• ~65–70%: Both-twin survival, laser (vs ~40% historical amnioreduction)
• ↓TAPS, ↓recurrence: Solomon vs selective technique (Solomon RCT, Lancet 2014)

Procedure technique and comparison of management options

Fetoscopic laser photocoagulation procedure: • Percutaneous trocar placed under ultrasound guidance into the recipient (polyhydramniotic) sac — this larger fluid pocket provides working space and a favorable window • A fetoscope with an operative laser fiber is advanced to visualize the chorionic plate vascular equator — the line separating the donor and recipient placental territories • Every crossing vessel (AA, VV, and AV anastomoses) along the equator is coagulated; the Solomon technique extends the ablation line to connect all identified vessels into one continuous coagulated strip, reducing residual small-caliber anastomoses left behind by purely selective ablation • Amnioreduction of the recipient's excess fluid is typically performed at the end of the same procedure to normalize uterine volume and reduce preterm labor risk

Comparison of management strategies: • Expectant management: reserved for Stage I only, with close surveillance; risk of progression • Serial amnioreduction: removes excess recipient fluid to relieve maternal discomfort/preterm labor risk and modestly improve donor perfusion by reducing intra-amniotic pressure, but does NOT address the underlying vascular anastomoses — historical survival ~55–60% for ≥1 twin, now largely superseded by laser where available • Fetoscopic laser photocoagulation: definitive treatment; addresses the anastomoses directly; superior survival and lower neurologic morbidity than amnioreduction in randomized and registry data (Eurofetus trial; Senat et al., NEJM 2004) • Selective (bipolar cord) reduction: sacrifice of one twin's umbilical cord, reserved for Stage V, severely discordant structural/genetic anomaly, or laser failure with one twin in extremis, to protect the co-twin from the hemodynamic consequences of demise

Post-Laser Surveillance — Fluid Normalization, TAPS, and Ongoing MC Twin Monitoring

After successful laser, fluid volumes normalize over 1–2 weeks as the donor twin resumes urine production and the recipient's polyuria resolves; surveillance then focuses on detecting two important post-laser complications — recurrent TTTS from missed or recanalized anastomoses, and twin anemic-polycythemic sequence (TAPS) from small residual AV anastomoses causing a slow, chronic transfusion without the fluid discordance of classic TTTS.

• 1–2 wks: Fluid normalization (post-laser)
• 2–13%: Post-laser TAPS incidence (spontaneous or post-laser)
• MCA-PSV: TAPS diagnostic tool (discordant PSV between twins)
• <5%: Recurrent TTTS incidence (with Solomon technique)

Surveillance protocol after laser and for all monochorionic twins

Post-laser surveillance schedule: • Ultrasound within 24–48 hours to confirm both twins are alive and to assess fluid trend • Weekly ultrasound with MCA-PSV in both twins for 2–4 weeks to screen for TAPS (donor PSV >1.5 MoM = anemia; recipient PSV <1.0 MoM = polycythemia) and to confirm fluid volumes are normalizing rather than recurring • Fetal echocardiography to document resolution of recipient cardiomyopathy • Once stable, surveillance reverts to the standard biweekly (every 2 week) protocol recommended for ALL monochorionic diamniotic twin pregnancies starting at 16 weeks, continued for the remainder of gestation regardless of TTTS history — because MC placentation carries baseline risks (selective fetal growth restriction, TAPS, single fetal demise) independent of prior TTTS • Delivery typically planned at 34–37 weeks for uncomplicated post-laser MC twins, earlier if growth restriction, recurrent TTTS, or other complications supervene

Every monochorionic diamniotic twin pregnancy — whether or not TTTS ever develops — requires ultrasound surveillance at least every two weeks from 16 weeks gestation, because the same anastomotic vascular bed that causes TTTS also underlies selective growth restriction and TAPS, both of which can arise de novo without ever meeting Quintero criteria.